Analysts forecast that T2 Biosystems (NASDAQ:TTOO) will post earnings of ($0.39) per share for the current quarter, according to Zacks. Three analysts have made estimates for T2 Biosystems’ earnings, with estimates ranging from ($0.43) to ($0.35). T2 Biosystems posted earnings per share of ($0.48) during the same quarter last year, which would indicate a positive year over year growth rate of 18.8%. The company is expected to report its next quarterly earnings results on Tuesday, May 1st.
According to Zacks, analysts expect that T2 Biosystems will report full year earnings of ($1.51) per share for the current fiscal year, with EPS estimates ranging from ($1.59) to ($1.38). For the next fiscal year, analysts expect that the firm will post earnings of ($1.10) per share, with EPS estimates ranging from ($1.25) to ($0.95). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that cover T2 Biosystems.
TTOO has been the topic of a number of recent research reports. Zacks Investment Research lowered T2 Biosystems from a “buy” rating to a “hold” rating in a report on Tuesday, April 3rd. ValuEngine upgraded T2 Biosystems from a “strong sell” rating to a “sell” rating in a report on Monday, March 19th. HC Wainwright set a $8.00 price target on T2 Biosystems and gave the stock a “buy” rating in a report on Monday, February 12th. Finally, Goldman Sachs assumed coverage on T2 Biosystems in a report on Monday, January 29th. They set a “neutral” rating and a $5.20 price target on the stock. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. T2 Biosystems has an average rating of “Hold” and an average price target of $6.12.
TTOO stock opened at $6.82 on Friday. T2 Biosystems has a twelve month low of $2.50 and a twelve month high of $7.53. The company has a quick ratio of 0.83, a current ratio of 0.86 and a debt-to-equity ratio of 1.29.
Institutional investors have recently modified their holdings of the stock. Point72 Asset Management L.P. bought a new stake in T2 Biosystems during the third quarter worth $630,000. Renaissance Technologies LLC lifted its holdings in T2 Biosystems by 72.2% during the fourth quarter. Renaissance Technologies LLC now owns 83,500 shares of the medical equipment provider’s stock worth $344,000 after acquiring an additional 35,000 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in T2 Biosystems by 41.9% during the fourth quarter. Geode Capital Management LLC now owns 134,470 shares of the medical equipment provider’s stock worth $554,000 after acquiring an additional 39,722 shares during the period. Institutional investors and hedge funds own 52.33% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Analysts Anticipate T2 Biosystems (TTOO) Will Announce Earnings of -$0.39 Per Share” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/04/17/analysts-anticipate-t2-biosystems-ttoo-will-announce-earnings-of-0-39-per-share.html.
T2 Biosystems Company Profile
T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine.
Get a free copy of the Zacks research report on T2 Biosystems (TTOO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.